The re-emergence of tuberculosis: What have we learnt from molecular epidemiology?

Clinical Microbiology and Infection

Volumn 19, Issue 10, 2013, Pages 889-901

  Borgdorff, M W ^a,b   van Soolingen, D ^c,d  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; Molecular epidemiology; Phylogeography; Population dynamics; Risk factors; Transmission; Tuberculosis

Indexed keywords

VACCINE;

CONTAMINATION; DNA FINGERPRINTING; DRUG RESISTANT TUBERCULOSIS; DYNAMICS; GENOME; GENOTYPE; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; INCUBATION TIME; LABORATORY; MIXED INFECTION; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MULTIDRUG RESISTANCE; PHYLOGEOGRAPHY; POPULATION STRUCTURE; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; TUBERCULOSIS; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM TUBERCULOSIS;

DRUG RESISTANCE; MOLECULAR EPIDEMIOLOGY; PHYLOGEOGRAPHY; POPULATION DYNAMICS; RISK FACTORS; TRANSMISSION; TUBERCULOSIS;

COMMUNICABLE DISEASES, EMERGING; HUMANS; MOLECULAR EPIDEMIOLOGY; PHYLOGEOGRAPHY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84884708048     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12253     Document Type: Review

References (163)

1. World Health Organization. Global tuberculosis report 2012. Geneva: WHO, 2012.
2. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: European Centre for Disease Prevention and Control, 2013.
3. Styblo K. The elimination of tuberculosis in The Netherlands. Bull Int Union Tuberc Lung Dis 1990; 65: 49-55.
4. Dowdle WR. A strategic plan for the elimination of tuberculosis in the United States. MMWR 1989; 38(suppl 3): 1-25.
5. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
6. Alland D, Kalkut GE, Moss AR et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
7. Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
8. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276.
9. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global burden of disease study. Lancet 1997; 349: 1347-1352.
10. De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-465.
11. Espinal MA, Laszlo A, Simonsen L et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
12. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
13. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352: 1886-1891.
14. Styblo K. Epidemiology of tuberculosis. Selected papers 24. The Hague: KNCV Tuberculosis Foundation, 1992.
15. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68: 2240-2246.
16. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 2009; 87: 683-691.
17. Schurch AC, van Soolingen D. DNA fingerprinting of Mycobacterium tuberculosis: from phage typing to whole-genome sequencing. Infect Genet Evol 2012; 12: 602-609.
18. Brudey K, Driscoll JR, Rigouts L et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006; 6: 23.
19. Supply P, Allix C, Lesjean S et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-4510.
20. Brosch R, Gordon SV, Marmiesse M et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002; 99: 3684-3689.
21. Hershberg R, Lipatov M, Small PM et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 2008; 6: e311.
22. Namouchi A, Didelot X, Schöck U, Gicquel B, Rocha EP. After the bottleneck: genome-wide diversification of the Mycobacterium tuberculosis complex by mutation, recombination, and natural selection. Genome Res 2012; 22: 721-734.
23. Djelouadji Z, Arnold C, Gharbia S, Raoult D, Drancourt M. Multispacer sequence typing for Mycobacterium tuberculosis genotyping. PLoS ONE 2008; 18: 3.
24. Schurch AC, Kremer K, Daviena O et al. High-resolution typing by integration of genome sequencing data in a large tuberculosis cluster. J Clin Microbiol 2010; 48: 3403-3406.
25. Gardy JL, Johnston JC, Ho Sui SJ et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364: 730-739.
26. Walker TM, Ip CL, Harrell RH et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 2013; 13: 137-146.
27. Horwitz O. Disease, cure, and death: epidemiologic and clinical parameters for chronic diseases illustrated by a model-tuberculosis. Am J Epidemiol 1973; 97: 148-159.
28. Braden CR, Templeton GL, Cave MD et al. Interpretation of restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis 1997; 175: 1446-1452.
29. Van Deutekom H, Hoijng SP, de Haas PE et al. Clustered tuberculosis cases: do they represent recent transmission and can they be detected earlier? Am J Respir Crit Care Med 2004; 169: 806-810.
30. Jasmer RM, Hahn JA, Small PM et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999; 130: 971-978.
31. Glynn JR, Bauer J, de Boer AS et al. Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. European Concerted Action on Molecular Epidemiology and Control of Tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1055-1060.
32. Borgdorff MW, van der Werf MJ, de Haas PE, Kremer K, van Soolingen D. Tuberculosis elimination in the Netherlands. Emerg Infect Dis 2005; 11: 597-602.
33. de Boer AS, Borgdorff MW, de Haas PE, Nagelkerke NJ, van Embden JD, van Soolingen D. Analysis of rate of change of IS6110 RFLP patterns of Mycobacterium tuberculosis based on serial patient isolates. J Infect Dis 1999; 180: 1238-1244.
34. Glynn JR, Vynnycky E, Fine PE. Influence of sampling on estimates of clustering and recent transmission of Mycobacterium tuberculosis derived from DNA fingerprinting techniques. Am J Epidemiol 1999; 149: 366-371.
35. Murray M. Sampling bias in the molecular epidemiology of tuberculosis. Emerg Infect Dis 2002; 8: 363-369.
36. Vynnycky E, Nagelkerke N, Borgdorff MW, van Soolingen D, van Embden JD, Fine PE. The effect of age and study duration on the relationship between 'clustering' of DNA fingerprint patterns and the proportion of tuberculosis disease attributable to recent transmission. Epidemiol Infect 2001; 126: 43-62.
37. Houben RM, Glynn JR. A systematic review and meta-analysis of molecular epidemiological studies of tuberculosis: development of a new tool to aid interpretation. Trop Med Int Health 2009; 14: 892-909.
38. van Soolingen D, Borgdorff MW, de Haas PE et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180: 726-736.
39. Geng E, Kreiswirth B, Driver C et al. Changes in the transmission of tuberculosis in New York City from 1990-1999. N Engl J Med 2002; 346: 1453-1458.
40. Nava-Aguilera E, Andersson N, Harris E et al. Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2009; 13: 17-26.
41. Rodwell TC, Kapasi AJ, Barnes RF, Moser KS. Factors associated with genotype clustering of Mycobacterium tuberculosis isolates in an ethnically diverse region of southern California, United States. Infect Genet Evol 2012; 12: 1917-1925.
42. Love J, Sonnenberg P, Glynn JR et al. Molecular epidemiology of tuberculosis in England, 1998. Int J Tuberc Lung Dis 2009; 13: 201-207.
43. Borgdorff MW, Nagelkerke NJ, de Haas PE, van Soolingen D. Transmission of Mycobacterium tuberculosis depending on the age and sex of source cases. Am J Epidemiol 2001; 154: 934-943.
44. Borgdorff MW, van den Hof S, Kremer K et al. Progress towards tuberculosis elimination: secular trend, immigration and transmission. Eur Respir J 2010; 36: 339-347.
45. Borgdorff MW, van den Hof S, Kalisvaart N, Kremer K, van Soolingen D. Influence of sampling on clustering and associations with risk factors in the molecular epidemiology of tuberculosis. Am J Epidemiol 2011; 174: 243-251.
46. Kik SV, Verver S, van Soolingen D et al. Tuberculosis outbreaks predicted by characteristics of first patients in a DNA fingerprint cluster. Am J Respir Crit Care Med 2008; 178: 96-104.
47. de Vries G, van Hest RA, Richardus JH. Impact of mobile radiographic screening on tuberculosis among drug users and homeless persons. Am J Respir Crit Care Med 2007; 176: 201-207.
48. McNabb SJ, Kammerer JS, Hickey AC et al. Added epidemiologic value to tuberculosis prevention and control of the investigation of clustered genotypes of Mycobacterium tuberculosis isolates. Am J Epidemiol 2004; 160: 589-597.
49. Cronin WA, Golub JE, Lathan MJ et al. Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis 2002; 8: 1271-1279.
50. Ruddy MC, Davies AP, Yates MD et al. Outbreak of isoniazid resistant tuberculosis in north London. Thorax 2004; 59: 279-285.
51. Aspler A, Chong H, Kunimoto D et al. Sustained intra- and inter-jurisdictional transmission of tuberculosis within a mobile, multi-ethnic social network: lessons for tuberculosis elimination. Can J Public Health 2010; 101: 205-209.
52. Allix-Beguec C, Supply P, Wanlin M, Bifani P, Fauville-Dufaux M. Standardised PCR-based molecular epidemiology of tuberculosis. Eur Respir J 2008; 31: 1077-1084.
53. de Vries G, van Hest RA. From contact investigation to tuberculosis screening of drug addicts and homeless persons in Rotterdam. Eur J Public Health 2006; 16: 133-136.
54. Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998; 158: 465-469.
55. Verver S, Warren RM, Munch Z et al. Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet 2004; 363: 212-214.
56. Guerrero A, Cobo J, Fortun J et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 1997; 350: 1738-1742.
57. Moro ML, Gori A, Errante I et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998; 12: 1095-1102.
58. Samper S, Iglesias MJ, Rabanaque MJ et al. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J Clin Microbiol 2005; 43: 1220-1227.
59. Frieden TR, Woodley CL, Crawford JT, Lew D, Dooley SM. The molecular epidemiology of tuberculosis in New York City: the importance of nosocomial transmission and laboratory error. Tuber Lung Dis 1996; 77: 407-413.
60. French AL, Welbel SF, Dietrich SE et al. Use of DNA fingerprinting to assess tuberculosis infection control. Ann Intern Med 1998; 129: 856-861.
61. Escombe AR, Moore DA, Gilman RH et al. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 2008; 5: e188.
62. Escombe AR, Oeser C, Gilman RH et al. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis 2007; 44: 1349-1357.
63. Escombe AR, Oeser CC, Gilman RH et al. Natural ventilation for the prevention of airborne contagion. PLoS Med 2007; 4: e68.
64. Small PM, McClenny NB, Singh SP, Schoolnik GK, Tompkins LS, Mickelsen PA. Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. J Clin Microbiol 1993; 31: 1677-1682.
65. Jasmer RM, Roemer M, Hamilton J et al. A prospective, multicenter study of laboratory cross-contamination of Mycobacterium tuberculosis cultures. Emerg Infect Dis 2002; 8: 1260-1263.
66. Martin A, Herranz M, Lirola MM, Fernandez RF, Bouza E, Garcia de Viedma D. Optimized molecular resolution of cross-contamination alerts in clinical mycobacteriology laboratories. BMC Microbiol 2008; 8: 30.
67. de Boer AS, Blommerde B, de Haas PE et al. False-positive Mycobacterium tuberculosis cultures in 44 laboratories in The Netherlands (1993 to 2000): incidence, risk factors, and consequences. J Clin Microbiol 1993; 2002: 4004-4009.
68. Blower SM, McLean AR, Porco TC et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1995; 1: 815-821.
69. Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273: 497-500.
70. Vynnycky E, Borgdorff MW, Leung CC, Tam CM, Fine PE. Limited impact of tuberculosis control in Hong Kong: attributable to high risks of reactivation disease. Epidemiol Infect 2008; 136: 943-952.
71. van Rie A, Warren R, Richardson M et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
72. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
73. Crampin AC, Mwaungulu JN, Mwaungulu FD et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24: 417-426.
74. Houben RM, Glynn JR, Mboma S et al. The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. AIDS 2012; 26: 2233-2239.
75. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2005; 24: 685-691.
76. Jasmer RM, Bozeman L, Schwartzman K, Burman WJet al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-1366.
77. Verver S, Warren RM, Beyers N et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435.
78. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis 2010; 201: 704-711.
79. Lahey T, Mackenzie T, Arbeit RD et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis 2013; 56: 151-158.
80. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-287.
81. Chiang CY, Riley LW. Exogenous reinfection in tuberculosis. Lancet Infect Dis 2005; 5: 629-636.
82. Nagelkerke NJ, de Vlas SJ, Mahendradhata Y, Ottenhoff TH, Borgdorff M. Tuberculosis (Edinb) 2006; 86: 41-46.
83. Van Duin JM, Pijnenburg JE, van Rijswoud CM, de Haas PE, Hendriks WD, van Soolingen D. Investigation of cross contamination in a Mycobacterium tuberculosis laboratory using IS6110 DNA fingerprinting. Int J Tuberc Lung Dis 1998; 2: 425-429.
84. de Boer AS, Kremer K, Borgdorff MW, de Haas PE, Heersma HF, van Soolingen D. Genetic heterogeneity in Mycobacterium tuberculosis isolates reflected in IS6110 restriction fragment length polymorphism patterns as low-intensity bands. J Clin Microbiol 2000; 38: 4478-4484.
85. Rinder H, Mieskes KT, Loscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2001; 5: 339-345.
86. Kritzinger FE, Den BS, Verver S et al. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop Med Int Health 2009; 14: 136-142.
87. Warren RM, Victor TC, Streicher EM et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004; 169: 610-614.
88. Wang JY, Hsu HL, Yu MC et al. Mixed infection with Beijing and non-Beijing strains in pulmonary tuberculosis in Taiwan: prevalence, risk factors, and dominant strain. Clin Microbiol Infect 2011; 17: 1239-1245.
89. Huang HY, Tsai YS, Lee JJ et al. Mixed infection with Beijing and non-Beijing strains and drug resistance pattern of Mycobacterium tuberculosis. J Clin Microbiol 2010; 48: 4474-4480.
90. Mallard K, McNerney R, Crampin AC et al. Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga District, Malawi. J Clin Microbiol 2010; 48: 4512-4518.
91. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26: 28-106.
92. Sutherland I. The ten year incidence of clinical tuberculosis following 'conversion' in 2550 individuals aged 14 to 19 at the time of conversion. TSRU Progress Report 1968. The Hague: KNCV Tuberculosis Foundation, 1968.
93. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol 2011; 40: 964-970.
94. Niemann S, Rusch-Gerdes S, Richter E. IS6110 fingerprinting of drug-resistant Mycobacterium tuberculosis strains isolated in Germany during 1995. J Clin Microbiol 1997; 35: 3015-3020.
95. Viljanen MK, Vyshnevskiy BI, Otten TF et al. Survey of drug-resistant tuberculosis in northwestern Russia from 1984 through 1994. Eur J Clin Microbiol Infect Dis 1998; 17: 177-183.
96. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR 2006; 55: 301-305.
97. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 2010; 24: 705-725.
98. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
99. Gandhi NR, Shah NS, Andrews JR et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
100. Velayati AA, Masjedi MR, Farnia P et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-425.
101. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
102. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci USA 2000; 97: 8180-8185.
103. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
104. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
105. Moss AR, Alland D, Telzak E et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1997; 1: 115-121.
106. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
107. Gagneux S, Burgos MV, Deriemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: e61.
108. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000; 182: 1788-1790.
109. Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011; 17: 815-820.
110. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City-turning the tide. N Engl J Med 1995; 333: 229-233.
111. Deriemer K, Garcia-Garcia L, Bobadilla-Del-valle M et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245.
112. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-87.
113. Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: 843-849.
114. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 2010; 10: 103-111.
115. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis. 2006; 12: 736-743.
116. Devaux I, Kremer K, Heersma H, van Soolingen D. Clusters of multidrug-resistant Mycobacterium tuberculosis cases. Europe. Emerg Infect Dis 2009; 15: 1052-1060.
117. Devaux I, Manissero D, Fernandez de la Hoz K, Kremer K, van Soolingen D; EuroTB network. Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007. Euro Surveill 2010; 15: 19518.
118. Burgos M, Deriemer K, Small PM, Hopewell PC, Daley CL. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis 2003; 188: 1878-1884.
119. Metcalfe JZ, Kim EY, Lin SY et al. Determinants of multidrug-resistant tuberculosis clusters, California, USA, 2004-2007. Emerg Infect Dis 2010; 16: 1403-1409.
120. van Soolingen D, Qian L, de Haas PE et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 1995; 33: 3234-3238.
121. Anh DD, Borgdorff MW, Van LN et al. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 2000; 6: 302-305.
122. Kremer K, Glynn JR, Lillebaek T et al. Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers. J Clin Microbiol 2004; 42: 4040-4049.
123. Mokrousov I, Narvskaya O, Otten T et al. Phylogenetic reconstruction within Mycobacterium tuberculosis Beijing genotype in northwestern Russia. Res Microbiol 2002; 153: 629-637.
124. Kremer K, van-der-Werf MJ, Au BK et al. Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains. Emerg Infect Dis 2009; 15: 335-339.
125. Schurch AC, Kremer K, Warren RM et al. Mutations in the regulatory network underlie the recent clonal expansion of a dominant subclone of the Mycobacterium tuberculosis Beijing genotype. Infect Genet Evol 2011; 11: 587-597.
126. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002; 10: 45-52.
127. Caminero JA, Pena MJ, Campos-Herrero MI et al. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island. Am J Respir Crit Care Med 2001; 164: 1165-1170.
128. Cowley D, Govender D, February B et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis 2008; 47: 1252-1259.
129. Borgdorff MW, de Haas P, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype, the Netherlands. Emerg Infect Dis 2003; 9: 1310-1313.
130. Johnson R, Warren RM, van der Spuy GD et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis 2010; 14: 119-121.
131. Ferro BE, Nieto LM, Rozo JC, Forero L, van Soolingen D. Multidrug-resistant Mycobacterium tuberculosis, Southwestern Colombia. Emerg Infect Dis 2011; 17: 1259-1262.
132. Schurch AC, Kremer K, Hendriks AC et al. SNP/RD typing of Mycobacterium tuberculosis Beijing strains reveals local and worldwide disseminated clonal complexes. PLoS ONE 2011; 6: e28365.
133. de Steenwinkel JE, ten Kate MT, de Knegt GJ et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis 2012; 18: 660-663.
134. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7: 328-337.
135. Schurch AC, Kremer K, Kiers A, Boeree MJ, Siezen RJ, van Soolingen D. Preferential deletion events in the direct repeat locus of Mycobacterium tuberculosis. J Clin Microbiol 2011; 49: 1318-1322.
136. Wirth T, Hildebrand F, Allix-Beguec C et al. Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog 2008; 4: e1000160.
137. Reyes JF, Chan CH, Tanaka MM. Impact of homoplasy on variable numbers of tandem repeats and spoligotypes in Mycobacterium tuberculosis. Infect Genet Evol 2012; 12: 811-818.
138. Gagneux S, Deriemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 2869-2873.
139. Baker L, Brown T, Maiden MC, Drobniewski F. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg Infect Dis 2004; 10: 1568-1577.
140. Falush D, Wirth T, Linz B et al. Traces of human migrations in Helicobacter pylori populations. Science 2003; 299: 1582-1585.
141. van Soolingen D, Hoogenboezem T, de Haas PE et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol 1997; 47: 1236-1245.
142. Somoskovi A, Dormandy J, Parsons LM et al. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: identification of a species-specific pncA mutation in 'Mycobacterium canettii' and the reliable and rapid predictor of pyrazinamide resistance. J Clin Microbiol 2007; 45: 595-599.
143. Caws M, Thwaites G, Dunstan S et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008; 4: e1000034.
144. van Crevel R, Parwati I, Sahiratmadja E et al. Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. J Infect Dis 2009; 200: 1671-1674.
145. Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
146. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378: 57-72.
147. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
148. Svensson E, Millet J, Lindqvist A, Olsson M, Ridell M, Rastogi N. Impact of immigration on tuberculosis epidemiology in a low-incidence country. Clin Microbiol Infect 2011; 17: 881-887.
149. Sails AD, Barrett A, Sarginson S et al. Molecular epidemiology of Mycobacterium tuberculosis in East Lancashire 2001-2009. Thorax 2011; 66: 709-713.
150. Dahle UR, Eldholm V, Winje BA, Mannsaker T, Heldal E. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med 2007; 176: 930-935.
151. Vanhomwegen J, Kwara A, Martin M et al. Impact of immigration on the molecular epidemiology of tuberculosis in Rhode Island. J Clin Microbiol 2011; 49: 834-844.
152. Liu Y, Weinberg MS, Ortega LS, Painter JA, Maloney SA. Overseas screening for tuberculosis in US-bound immigrants and refugees. N Engl J Med 2009; 360: 2406-2415.
153. Schwartzman K, Oxlade O, Barr RG et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353: 1008-1020.
154. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
155. Saunders NJ, Trivedi UH, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J Infect 2011; 62: 212-217.
156. van Deutekom H, Supply P, de Haas PE et al. Molecular typing of Mycobacterium tuberculosis by mycobacterial interspersed repetitive unit-variable-number tandem repeat analysis, a more accurate method for identifying epidemiological links between patients with tuberculosis. J Clin Microbiol 2005; 43: 4473-4479.
157. Sandegren L, Groenheit R, Koivula T et al. Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. PLoS ONE 2011; 6: e16647.
158. Schurch AC, Kremer K, Kiers A et al. The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol 2010; 10: 108-114.
159. de Jong BC, Hill PC, Aiken A et al. Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis 2008; 198: 1037-1043.
160. Verhagen LM, van den Hof S, van Deutekom H et al. Mycobacterial factors relevant for transmission of tuberculosis. J Infect Dis 2011; 203: 1249-1255.
161. Click ES, Moonan PK, Winston CA, Cowan LS, Oeltmann JE. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 2012; 54: 211-219.
162. Buu TN, Huyen MN, van Soolingen D et al. The Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment failure in Vietnam. Clin Infect Dis 2010; 51: 879-886.
163. Lan NT, Lien HT, Tung LB, Borgdorff MW, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis 2003; 9: 1633-1635.